|  |  |  |  |
| --- | --- | --- | --- |
| A Comparative Multicentric Non-Infireority Clinical Trial of WHOMBMDT with a New Monthly Chemotherapy Regime containing Rifampicin, Moxifloxacin and Clarithromycin (RMC) on Multibacillary patients from IndiaStandard Operating Procedure 5Skin Biopsy and Histopathology | | | |
| SOP Ref: TLMTI\_RMC -SOP-3 | | | |
| Version: Draft v | | | |
| Author: Joydeepa Darlong Title: Molecular Viability Assay (MVA) | | | |
| Effective Date: |  | Review by: |  |
| Approved by: |  | Date: |  |
| Signature of Authorisor: |  | | |

|  |  |  |  |
| --- | --- | --- | --- |
| **SOP Chronology** | | |  |
| **Version** | **Date** | **Reason for Change** | **Author** |
| 1.0 |  |  | JD |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |
| --- | --- |
| **Table of Contents** | **Page** |
| 1. Purpose | 3 |
| 2. Background | 3 |
| 3. Scope | 3 |
| 5. Procedure | 3-6 |
| 6. Appendices  Appendix 1 | 7  Separate document |

**1.** **PURPOSE**

This document describes the process of collection, preparation and examination Mouse Foot Pad (MFP) samples taken from patients for the RMC study.

**2. Background**

Current WHOMDT does not kill 100% bacteria even after a full course of treatment in a subset of patients harboring a large bacterial load thus continuing transmission of the disease responsible for endemicity in some countries. The duration of MDT is long and promotes noncompliance. MDT continues to be controversial with limited evidence support resulting in multiple reformulations since the last 40 years. This calls for a search for newer, more efficacious drugs with shorter duration of action evidenced with well-designed clinical trials. Relapse, advocated as the key outcome measure of efficacy of MDT, has its drawbacks. Relapse studies require long years of follow up. The gold standard test for viability was Mouse foot pad studies which is costly and time consuming. Hence, we propose Molecular Viability Assays as outcome measure of efficacy which are newer and better techniques to test viability faster.

In this study, we propose to conduct a Randomized Controlled study comparing WHO MBMDT with a monthly regime consisting of currently most bactericidal and safe drugs of Rifampicin, Moxifloxacin and Clarithromycin in MB leprosy patients.

**3. SCOPE**

This document applies to all staff involved in collection, preparation and examination of Mouse Foot Pad (MFP) samples.

**4. PROCEDURE**